Suvretta Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Suvretta Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,222,700	Closed	-$72.4M	–	57
2016 Q4	$72.4M	Buy	+1,222,700	New	+$75.5M	1.87%	15

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Suvretta Capital Management's XBI Position: Q1 2017 in Review

Suvretta Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 1,222,700 shares — an estimated $72.4M sold.

Suvretta Capital Management first reported a position in XBI in Q4 2016 and held it in 1 quarter. The position peaked at $72.4M in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

Suvretta Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
Suvretta Capital Management sold 1,222,700 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $72.4M.
Suvretta Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 1 quarter.
Suvretta Capital Management's State Street SPDR S&P Biotech ETF position peaked at $72.4M in Q4 2016.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Suvretta Capital Management's 13F filing for Q1 2017, filed 15 May 2017.